| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2023 |
|
|
2022 |
|
| |
|
For
the Three Months Ended
January
31,
|
|
| |
|
2023 |
|
|
2022 |
|
| Net
loss: |
|
|
|
|
|
|
|
|
| CAR-T
Therapeutics |
|
$ |
(911 |
) |
|
$ |
(1,611 |
) |
| Cancer
Vaccines |
|
|
(958 |
) |
|
|
(1,357 |
) |
| Anti-Viral
Therapeutics |
|
|
(482 |
) |
|
|
(904 |
) |
| Other |
|
|
(3 |
) |
|
|
(7 |
) |
| Total |
|
$ |
(2,354 |
) |
|
$ |
(3,879 |
) |
| Net Loss |
|
$ |
(2,354 |
) |
|
$ |
(3,879 |
) |
| |
|
|
|
|
|
|
|
|
| Total
operating costs and expenses |
|
$ |
2,556 |
|
|
$ |
3,880 |
|
| Less
non-cash share-based compensation |
|
|
(1,063 |
) |
|
|
(2,354 |
) |
| Operating
costs and expenses excluding non-cash share-based compensation |
|
$ |
1,493 |
|
|
$ |
1,526 |
|
Operating
costs and expenses excluding non-cash
share based compensation expense: |
|
|
|
|
|
|
|
|
| CAR-T
Therapeutics |
|
$ |
598 |
|
|
$ |
669 |
|
| Cancer
Vaccines |
|
|
588 |
|
|
|
480 |
|
| Anti-Viral
Therapeutics |
|
|
305 |
|
|
|
372 |
|
| Other |
|
|
2 |
|
|
|
5 |
|
| Total |
|
$ |
1,493 |
|
|
$ |
1,526 |
|
| Operating
costs and expenses excluding non-cash based compensation |
|
$ |
1,493 |
|
|
$ |
1,526 |
|
| |
|
|
|
|
|
|
|
|
| |
|
January
31,
2023 |
|
|
October
31,
2022 |
|
| Total
assets: |
|
|
|
|
|
|
|
|
| CAR-T
Therapeutics |
|
$ |
11,318 |
|
|
$ |
16,921 |
|
| Cancer
Vaccines |
|
|
11,098 |
|
|
|
9,442 |
|
| Anti-Viral
Therapeutics |
|
|
5,750 |
|
|
|
3,811 |
|
| Other |
|
|
140 |
|
|
|
238 |
|
| Total |
|
$ |
28,306 |
|
|
$ |
30,412 |
|
| Total assets |
|
$ |
28,306 |
|
|
$ |
30,412 |
|
|